July 29, 2019 07:47 AM EDTUpdated 09:35 AM

$20B-plus? Merck keeps racking up PhIII successes, scoring on triple negative breast cancer challenge as analysts drive up peak sales estimates

John Carroll

Editor & Founder

Just days after Bristol-Myers Squibb managed to surprise the analyst brigade with a Phase III flop for its PD-1 checkpoint Opdivo combined with chemo …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

$20B-plus? Merck keeps racking up PhIII successes, scoring on triple negative breast cancer challenge as analysts drive up peak sales estimates

John Carroll

Editor & Founder

Sign up to read this article for free.

FDA approves subcutaneous version of Bristol Myers' Opdivo

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

$20B-plus? Mer­ck keeps rack­ing up PhI­II suc­cess­es, scor­ing on triple neg­a­tive breast can­cer chal­lenge as an­a­lysts dri­ve up peak sales es­ti­mates

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

$20B-plus? Merck keeps racking up PhIII successes, scoring on triple negative breast cancer challenge as analysts drive up peak sales estimates

FDA approves subcutaneous version of Bristol Myers' Opdivo

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?